Status:
RECRUITING
Myeloma Registry Platform (MYRIAM)
Lead Sponsor:
iOMEDICO AG
Collaborating Sponsors:
Deutsche Studiengruppe Multiples Myelom (DSMM)
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristi...
Detailed Description
MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple my...
Eligibility Criteria
Inclusion
- MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment)
- Age ≥ 18 years
- Written informed consent
- Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment
- Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment
- Sufficient German language skills for participation in the PRO satellite
Exclusion
- No systemic therapy for myeloma
- Patients already enrolled in studies that prohibit any participation in other studies
Key Trial Info
Start Date :
September 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
2200 Patients enrolled
Trial Details
Trial ID
NCT03308474
Start Date
September 25 2017
End Date
December 1 2028
Last Update
October 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple sites all over germany
Multiple Locations, Germany